In silico analysis is a promising way of detecting potential drugs, virtually allowing us to understand the receptor-ligand interaction ( 19). (2020) showed that grapefruit seed extract (GSE) plus xylitol as a nasal spray solution can be used as a potential adjunct treatment of COVID-19 ( 18). (2019) GSE showed anti-viral activity against enveloped viruses, but not against non-enveloped viruses ( 17). The secondary metabolites of grapefruit seeds are predominately limonoids and flavonoids, such as limonin, naringin, narirutin or naringenin and hesperidin ( 14, 15, 16). GSE has strong antibacterial, anti-fungal, antiviral, liver-protective, antioxidant, neuroprotective, cardioprotective activity and many other bioactive properties, because of its high content of flavonoids, ascorbic acid, tocopherol, citric acid, limonoids, sterols, minerals and numerous other bioactive substances ( 13). and Citrus × sinensis, (L.) Osbec from Barbados ( 14). It has originated as a natural hybrid of Citrus maxima, Merr. Grapefruit ( Citrus × paradisi, Macfad) is a subtropical fruit that belongs to the Rutaceae family. One such potential antiviral substance is grapefruit seed extract (GSE), a commercial product made from grapefruit seeds and pulp, that is often used as a dietary supplement ( 13). In order to stop the global pandemic, numerous studies and trials of potential drugs against SARS-COV-2 are underway ( 12). Because of its important role in viral replication and its highly conserved catalytic domains, main protease is a potential drug target ( 11).įinding an effective cure or vaccine against SARS-CoV-2 represents a great challenge to humanity. Proteolytic cleavage is performed by papain-pike protease (PL pro) and the main protease (M pro), releasing functional polypeptides from the pp1a and pp1ab polyproteins ( 10, 11). Main role of M pro in viral replication is its proteolytic activity. M pro is highly conserved among all of the Coronaviruses ( 8). The active site of this enzyme contains four sites, S1', S1, S2, and S4 ( 8, 9), while the catalytic site of M pro preserves catalytic diad (His41-Cys145) located between domain I and II ( 7). Domain III has enzymatic activity and no role in binding ( 7). Chymotrypsin-like cysteine protease (306 amino acid residues) ( 6) has three domains: catalytic domain, C-terminal domain and N-terminal finger domain, labeled as domain I, domain II and domain III, respectively. Nsp-5 encodes the main protease known as M pro (chymotrypsin-like cysteine protease, 3CL pro), with an important role in virus replication and gene expression ( 5). The first, the largest open reading frame, encodes 16 non-structural proteins nsps (nsp1-nsp16) ( 4). Genomes of some typical Coronaviruses (CoVs), just like SARS-CoV-2 itself, have 6-10 open reading frames (ORFs). SARS-CoV-2 is a positive-sense single-stranded RNA (+ssRNA) virus which belongs to Betacoronavirus genus of the Coronaviridae family, causing coronavirus disease 2019 (COVID-19) with severe (13.8%) and critical symptoms (4.7%) in some cases, including deadly dangerous fatal pneumonia ( 2, 3). Gustavo Ferrer, an acclaimed pulmonologist and former WHO infectious disease researcher that has been running two ICUs in Miami and a Covid subject matter expert for most national media outlets are available for interviews or to provide any additional information.Since the outbreak of the SARS-CoV-2 virus, from December 2019 until May 2021, more than 157 million people have been infected, and over 3.2 million deaths have been recorded ( 1). The clinical trials are ongoing however with a twenty-year safety record Xlear is hoping that people can start using the Xlear nasal spray as an adjunct to other safety measures such as wearing a mask and social distancing.īoth Xlear CEO & Founder Nathan Jones and Dr. All of the patients in the trials have symptoms, have tested positive by PCR, and also have underlying health conditions. In short, within days of starting to use the nasal spray the patients have become asymptomatic, and within 7 days they are testing negative by PCR. It is the first paper published with regards to actual human clinical trials. The paper published last week has shown very promising results. Xlear is an over-the-counter (OTC) nasal spray that has been on the market both in the United States and abroad for more than two decades and is available at most pharmacies, grocery stores and online. Several InVitro studies over the past few months have shown that Xlear nasal spray is extremely effective at both blocking viral adhesion of the Sars-cov-2 and also destroying the virus. is proud to share the first results of the ongoing clinical trials using Xlear nasal spray as an adjunct treatment for people that have been exposed to Sars-cov-2. AMERICAN FORK, Utah-( BUSINESS WIRE)-Xlear Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |